ClinicalTrials.gg
Active, not recruitingNCT07116889Updated Nov 5, 2025

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

A Phase 1 interventional study of GB-0895 (SC) and GB-0895 (SC) in Asthma and COPD (Chronic Obstructive Pulmonary Disease), sponsored by Generate Biomedicines. Active, not recruiting at 13 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-05.

Sponsored by Generate Biomedicines · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Dec 2023, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Planned enrollment
566th of 1,353
156 · median 100
Started
2023
with 54 others
Phase 1
128 of 1,695
11 open now
Primary completion
2027-05
later than 84 of 183 live
Registered
1,632nd of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 566th largest by planned enrollment of the 1,353 interventional ones that give a count, is one of 55 that started in 2023, is one of 128 in phase 1, reaches primary completion later than 84 of the 183 other live ones, and was the 1,632nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.

03

Conditions studied

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • Generate Biomedicines
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part A \& B, Asthma):

  • Participants must be able to give written consent
  • 18 to 65 years of age (inclusive) at the screening visit;
  • Diagnoses of mild to moderate asthma for ≥12 months
  • Laboratory blood values within the ranges outlined in the protocol

Exclusion Criteria (Part A \& B, Asthma):

  • Other serious disease
  • Significant asthma exacerbations
  • Current smokers or ex-smokers with >5 pack years smoking history
  • Pregnant or breastfeeding

Inclusion Criteria (Part C, ):

  • Participants must be able to give written consent
  • 40 to 80 years of age (inclusive) at the screening visit;
  • Diagnoses of COPD for ≥12 months
  • Laboratory blood values within the ranges outlined in the protocol
  • Must be current or ex-smoker

Exclusion Criteria (Part C, COPD):

  • Other serious disease
  • COPD exacerbation within 4 weeks of enrolling
  • Requires supplemental oxygen (CPAP for sleep apnea allowed)
  • Pregnant or breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD) (asthma participants)

    randomized 3:1 active:placebo

    Biological: GB-0895 (SC) · Drug: Placebo (SC)

  • Experimental
    Part B: Multiple Ascending Dose (MAD) (asthma participants)

    randomized 3:1 active:placebo

    Biological: GB-0895 (SC) · Drug: Placebo (SC)

  • Experimental
    Part C: Single Dose (COPD participants)

    randomized 3:1 active:placebo

    Biological: GB-0895 (SC) · Drug: Placebo (SC)

Interventions

  • BiologicalGB-0895 (SC)

    Single subcutaneous dose of GB-0895

  • BiologicalGB-0895 (SC)

    Multiple subcutaneous doses of GB-0895

  • DrugPlacebo (SC)

    Single subcutaneous dose of placebo

  • DrugPlacebo (SC)

    Multiple subcutaneous doses of placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment related adverse events as assessed by CTCAE 5.0

    Time frame: Day 1 to Day 500

Secondary outcomes

  1. Measure of maximum plasma concentration of GB-0895

    Time frame: Day 1 to Day 500

  2. Total exposure of GB-0895 (AUC)

    Time frame: Day 1 to Day 500

  3. Blood eosinophil counts

    Time frame: Day 1 to Day 500

  4. Incidence of treatment-emergent anti-drug antibody (ADA) response

    Time frame: Day 1 to Day 500

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for May 2027, 41 months after the start.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 41 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 12, 2025
StartActual
Dec 12, 2023
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07116889
Lead sponsor
Generate Biomedicines
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Dec 12, 2023
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 5, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GB-0895

Start the discussion